Literature DB >> 28386764

Roles of tau protein in health and disease.

Tong Guo1, Wendy Noble1, Diane P Hanger2.   

Abstract

Tau is well established as a microtubule-associated protein in neurons. However, under pathological conditions, aberrant assembly of tau into insoluble aggregates is accompanied by synaptic dysfunction and neural cell death in a range of neurodegenerative disorders, collectively referred to as tauopathies. Recent advances in our understanding of the multiple functions and different locations of tau inside and outside neurons have revealed novel insights into its importance in a diverse range of molecular pathways including cell signalling, synaptic plasticity, and regulation of genomic stability. The present review describes the physiological and pathophysiological properties of tau and how these relate to its distribution and functions in neurons. We highlight the post-translational modifications of tau, which are pivotal in defining and modulating tau localisation and its roles in health and disease. We include discussion of other pathologically relevant changes in tau, including mutation and aggregation, and how these aspects impinge on the propensity of tau to propagate, and potentially drive neuronal loss, in diseased brain. Finally, we describe the cascade of pathological events that may be driven by tau dysfunction, including impaired axonal transport, alterations in synapse and mitochondrial function, activation of the unfolded protein response and defective protein degradation. It is important to fully understand the range of neuronal functions attributed to tau, since this will provide vital information on its involvement in the development and pathogenesis of disease. Such knowledge will enable determination of which critical molecular pathways should be targeted by potential therapeutic agents developed for the treatment of tauopathies.

Entities:  

Keywords:  Alzheimer’s disease; Microtubule binding; Propagation; Synaptic dysfunction; Tau; Tauopathy

Mesh:

Substances:

Year:  2017        PMID: 28386764      PMCID: PMC5390006          DOI: 10.1007/s00401-017-1707-9

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   17.088


  539 in total

1.  Proteasomal degradation of tau protein.

Authors:  Della C David; Robert Layfield; Louise Serpell; Yolanda Narain; Michel Goedert; Maria Grazia Spillantini
Journal:  J Neurochem       Date:  2002-10       Impact factor: 5.372

2.  Early N-terminal changes and caspase-6 cleavage of tau in Alzheimer's disease.

Authors:  Peleg M Horowitz; Kristina R Patterson; Angela L Guillozet-Bongaarts; Matthew R Reynolds; Christopher A Carroll; Susan T Weintraub; David A Bennett; Vincent L Cryns; Robert W Berry; Lester I Binder
Journal:  J Neurosci       Date:  2004-09-08       Impact factor: 6.167

3.  Pathogenic forms of tau inhibit kinesin-dependent axonal transport through a mechanism involving activation of axonal phosphotransferases.

Authors:  Nicholas M Kanaan; Gerardo A Morfini; Nichole E LaPointe; Gustavo F Pigino; Kristina R Patterson; Yuyu Song; Athena Andreadis; Yifan Fu; Scott T Brady; Lester I Binder
Journal:  J Neurosci       Date:  2011-07-06       Impact factor: 6.167

4.  Different immunoreactivities of the microtubule-binding region of tau and its molecular basis in brains from patients with Alzheimer's disease, Pick's disease, progressive supranuclear palsy and corticobasal degeneration.

Authors:  Tetsuaki Arai; Kenji Ikeda; Haruhiko Akiyama; Kuniaki Tsuchiya; Shuji Iritani; Koichi Ishiguro; Saburo Yagishita; Tatsuro Oda; Toshinari Odawara; Eizo Iseki
Journal:  Acta Neuropathol       Date:  2003-02-08       Impact factor: 17.088

5.  AD-linked, toxic NH2 human tau affects the quality control of mitochondria in neurons.

Authors:  G Amadoro; V Corsetti; F Florenzano; A Atlante; M T Ciotti; M P Mongiardi; R Bussani; V Nicolin; S L Nori; M Campanella; P Calissano
Journal:  Neurobiol Dis       Date:  2013-10-24       Impact factor: 5.996

6.  Selective tau tyrosine nitration in non-AD tauopathies.

Authors:  Juan F Reyes; Changiz Geula; Laurel Vana; Lester I Binder
Journal:  Acta Neuropathol       Date:  2011-11-06       Impact factor: 17.088

7.  Synaptic Contacts Enhance Cell-to-Cell Tau Pathology Propagation.

Authors:  Sara Calafate; Arjan Buist; Katarzyna Miskiewicz; Vinoy Vijayan; Guy Daneels; Bart de Strooper; Joris de Wit; Patrik Verstreken; Diederik Moechars
Journal:  Cell Rep       Date:  2015-05-14       Impact factor: 9.423

8.  Levels of kinesin light chain and dynein intermediate chain are reduced in the frontal cortex in Alzheimer's disease: implications for axoplasmic transport.

Authors:  Marina Morel; Céline Héraud; Charles Nicaise; Valérie Suain; Jean-Pierre Brion
Journal:  Acta Neuropathol       Date:  2011-11-18       Impact factor: 17.088

9.  Amyloid-β oligomers induce synaptic damage via Tau-dependent microtubule severing by TTLL6 and spastin.

Authors:  Hans Zempel; Julia Luedtke; Yatender Kumar; Jacek Biernat; Hana Dawson; Eckhard Mandelkow; Eva-Maria Mandelkow
Journal:  EMBO J       Date:  2013-09-24       Impact factor: 11.598

10.  Stepwise proteolysis liberates tau fragments that nucleate the Alzheimer-like aggregation of full-length tau in a neuronal cell model.

Authors:  Y P Wang; J Biernat; M Pickhardt; E Mandelkow; E-M Mandelkow
Journal:  Proc Natl Acad Sci U S A       Date:  2007-05-29       Impact factor: 11.205

View more
  225 in total

1.  Tau Diagnostics and Clinical Studies.

Authors:  Illana Gozes; Günter Höglinger; James P Quinn; Nigel M Hooper; Kina Höglund
Journal:  J Mol Neurosci       Date:  2017-10       Impact factor: 3.444

2.  Verapamil Inhibits Ser202/Thr205 Phosphorylation of Tau by Blocking TXNIP/ROS/p38 MAPK Pathway.

Authors:  Mariarosa Anna Beatrice Melone; Clemente Dato; Simona Paladino; Cinzia Coppola; Claudia Trebini; Maria Teresa Giordana; Lorena Perrone
Journal:  Pharm Res       Date:  2018-02-05       Impact factor: 4.200

3.  Selective Neuronal Vulnerability in Alzheimer's Disease: A Network-Based Analysis.

Authors:  Jean-Pierre Roussarie; Vicky Yao; Patricia Rodriguez-Rodriguez; Rose Oughtred; Jennifer Rust; Zakary Plautz; Shirin Kasturia; Christian Albornoz; Wei Wang; Eric F Schmidt; Ruth Dannenfelser; Alicja Tadych; Lars Brichta; Alona Barnea-Cramer; Nathaniel Heintz; Patrick R Hof; Myriam Heiman; Kara Dolinski; Marc Flajolet; Olga G Troyanskaya; Paul Greengard
Journal:  Neuron       Date:  2020-06-29       Impact factor: 17.173

4.  Regulatory mechanisms of tau protein fibrillation under the conditions of liquid-liquid phase separation.

Authors:  Solomiia Boyko; Krystyna Surewicz; Witold K Surewicz
Journal:  Proc Natl Acad Sci U S A       Date:  2020-12-01       Impact factor: 11.205

5.  Directed evolution of a picomolar-affinity, high-specificity antibody targeting phosphorylated tau.

Authors:  Dan Li; Lei Wang; Brandon F Maziuk; Xudong Yao; Benjamin Wolozin; Yong Ku Cho
Journal:  J Biol Chem       Date:  2018-06-13       Impact factor: 5.157

6.  Profiling of Argonaute-2-loaded microRNAs in a mouse model of frontotemporal dementia with parkinsonism-17.

Authors:  Aidan Kenny; Félix Hernández; Jesús Avila; José J Lucas; David C Henshall; Jochen Hm Prehn; Eva M Jiménez-Mateos; Tobias Engel
Journal:  Int J Physiol Pathophysiol Pharmacol       Date:  2018-12-25

7.  Quantitative Analysis of the Brain Ubiquitylome in Alzheimer's Disease.

Authors:  Measho H Abreha; Eric B Dammer; Lingyan Ping; Tian Zhang; Duc M Duong; Marla Gearing; James J Lah; Allan I Levey; Nicholas T Seyfried
Journal:  Proteomics       Date:  2018-10       Impact factor: 3.984

Review 8.  Alzheimer Disease: An Update on Pathobiology and Treatment Strategies.

Authors:  Justin M Long; David M Holtzman
Journal:  Cell       Date:  2019-09-26       Impact factor: 41.582

Review 9.  The structure and phase of tau: from monomer to amyloid filament.

Authors:  Yifan Zeng; Jing Yang; Bailing Zhang; Meng Gao; Zhengding Su; Yongqi Huang
Journal:  Cell Mol Life Sci       Date:  2020-10-19       Impact factor: 9.261

Review 10.  It's all about tau.

Authors:  Cheril Tapia-Rojas; Fabian Cabezas-Opazo; Carol A Deaton; Erick H Vergara; Gail V W Johnson; Rodrigo A Quintanilla
Journal:  Prog Neurobiol       Date:  2018-12-31       Impact factor: 11.685

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.